Along the line of research related to CD177, we have developed an immunohistochemistry protocol for CD177 on human cancer sections. We found that CD177 is not only expressed on cancer cells, but also on cancer-infiltrating regulatory T cells. Using state-of-the-art single cell RNAseq technology, we are defining the difference between CD177-positive vs. CD177-negative regulatory T cells in function. In addition, we are using genetic mouse models of CD177-deficiency to study the role of CD177 in regulatory T cells. CD177 is expressed on the surface that can be readily targetable by antibodies or other means. We are also interested in developing targeting antibodies for cancer immunotherapy.